Bareis' team found that, besides being diagnosed with schizophrenia, more than half (52%) of these patients also had ...

A novel psychiatric scale developed by colleagues of Gedeon Richter Plc. in collaboration with academia was also presented at ...

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

Phase 2 trial is designed to evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a ...

Flat affect is a possible symptom of schizophrenia. It is a term for a lack of emotional response. Learn more here.

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

I'm an Ivy League student at Columbia with schizophrenia, which causes hallucinations. I always see eels and lemons, so it's ...

Neurocrine Biosciences’ schizophrenia program pivot has failed. | Neurocrine Biosciences’ schizophrenia program pivot has ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in ...

There is no single test to diagnose schizophrenia. Healthcare professionals may use a variety of tests to rule out other ...